|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multivariate analysis showed that high PGRN expression, age (>66 years), stage (III), and perineural invasion (+) were independent prognostic factors associated with poor RFS after adjusting for confounding factors including sex, MSI, tumor location, KRAS, and lympho-vascular invasion.
|
30378010 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunotherapy might be a promising therapeutic approach in GEP-NENs especially in tumors with high TILs.
|
30608901 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gastroenteropancreatic neuroendocrine tumours (GEP NET) are a heterogeneous group of rare tumours that have distinct effects on the body due to their tumour location and potential to secrete hormones and peptides.
|
31550712 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GEP-NET primary tumor location or secretory syndrome did not influence the risk for MetS.
|
31533348 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We failed to find any association between the BALF content of progranulin or BCA-1 and the stage of tumor or prospectively assessed treatment response.
|
30357709 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we studied whether primary tumor site affects survival in patients with GEP-NETs and liver metastases (NELM).
|
30992703 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Silencing CCL5 expression in PGRN-deficient tumor reduces NK cell recruitment and restores tumor growth to the control level.
|
31491449 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results included the identification of 70% of SLN-negative patients who experienced metastasis as Class 2, the discovery of reduced recurrence-free survival for patients with thin tumors and Class 2B biology compared with that of those with Class 1A biology (P < .0001); and determination of the 31-GEP test as an independent predictor of risk compared with traditional staging factors in patients with stage I to IIA tumors.
|
30081113 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this chapter, we outlined our experimental procedures in determining the feasibility of novel mAb in the preclinical cancer model, with an example of progranulin (PGRN/GEP) mAb against hepatocellular carcinoma (HCC) tumor in mouse model.
|
29956274 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An in vivo study confirmed that the combined use of the two drugs displayed more potent antitumor activity compared to mice treated with cisplatin and GRN A alone; the inhibitory rate of tumor growth was 65.46% and 68.94%, respectively, in mice treated with GRN A and cisplatin.
|
30301274 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This chapter describes a number of approaches to measure the transcription level of the GRN gene and to detect and analyze PGRN expression in cancer cells and in the local environment of the tumor, in mouse and human samples.
|
29956276 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Transcriptome analysis of GEP-NET-derived cells, perturbed with a library of 107 compounds, identified the HDAC class I inhibitor entinostat as a potent inhibitor of master regulator activity for 42% of metastatic GEP-NET patients, abrogating tumor growth in vivo.
|
29915428 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When scoring is correlated to patient outcome, we have demonstrated that a patient with tumor PGRN/GP88/GEP staining of "3+" has a fivefold increased risk of disease recurrence within 5 years.
|
29956272 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In studies of mixed adeno-neuroendocrine carcinomas (MANECs) the molecular features of GEP-NEC largely resemble their carcinoma/adenocarcinomas tumor counterparts.
|
28456055 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are relatively rare tumors that arise from the diffuse neuroendocrine system, and the biggest advances in molecular biology have helped in understanding these biological diversity of tumors over the past decades.
|
27704598 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In previous years, progranulin (PGRN) has attracted increasing attention due to its oncogenic roles in several types of tumor.
|
29039535 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We have recently reported PGRN expression in islets and tumors developed in an MEN1 transgenic mouse.
|
26495792 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hierarchical clustering using all GEP genes showed that majority (61 of 71) of tumor samples clustered by patient, indicating greater interpatient heterogeneity (IPH) than ITH.
|
27185370 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study aimed to determine the expression of progranulin (PGRN) in hepatocellular carcinoma (HCC) cells in response to interleukin 6 (IL-6), a non-cellular component of the tumor microenvironment, and the molecular mechanism of PGRN oncogenic activity in hepatocarcinogenesis.
|
26879559 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, S1R1 depleted of PGRN also lost the ability to form tumor in an orthotopic xenograft mouse model.
|
24793792 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, the cumulative actuarial 5-year probability of metastatic death was 8.0 % for those with an insufficient/unsatisfactory aspirate for GEP classification or GEP class 1 tumor, versus 45.0 % for those with a GEP class 2 tumor (log rank P = 0.005).
|
24270974 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A characteristic of human gastroenteropancreatic neuroendocrine tumors (GEP-NET) is a minute unobtrusive primary tumor which often cannot be detected by common physical examinations.
|
21681495 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Granulin (GRN, or progranulin) is a protein involved in wound repair, inflammation, and neoplasia.
|
20489155 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Gastroenteropancreatic neuroendocrine tumors (GEP NETs) are relatively rare neoplasias arising from the embryonic neural crest, neuroectoderm and endoderm.
|
19125015 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Functional studies on Hep-2 cell lines demonstrated that the attenuation of PC cell-derived growth factor expression levels led to diminished cell proliferation rates (P<0.001), anchorage-independent growth in vitro (P<0.001), tumor forming in vivo (P<0.01) and resistance to apoptosis (P<0.001).
|
17159500 |
2007 |